I-Tirzepatide Injection ye-Diabetes kunye nokuLahla kobunzima

I-Tirzepatide yinoveli ye-glucose exhomekeke kwi-insulinotropic polypeptide (GIP) kunye ne-glucagon-like peptide-1 (GLP-1) i-agonist receptor ephuhlisiwe. Indlela yayo emibini ijolise ekuphuculeni ukukhuselwa kwe-insulin, ukucinezela ukukhutshwa kweglucagon, ukulibazisa ukukhupha isisu, kunye nokuphucula ukuhlutha, ukubonelela ngendlela yonyango ebanzi yohlobo lwe-2 yeswekile mellitus (T2DM) kunye nokutyeba.

Iziphumo eziphambili kwizifundo zeklinikhi

1. Ulawulo lweGlycemic

Ngaphakathi kwezininziUMDLALOisigaba 3 izilingo zeklinikhi, i-tirzepatide ibonakalisiweulawulo oluphezulu lwe-glycemicxa kuthelekiswa nee-antidiabetic agents ezikhoyo, kuquka i-semaglutide kunye ne-insulin degludec.

• Ithetha ukunciphisa i-HbA1c: ukuya kuthi ga−2.4%ukusuka kwisiseko emva kweeveki ezingama-40-52.

• Inani eliphezulu labathathi-nxaxheba liphunyeziweyoI-HbA1c <6.5%, ukuhlangana okanye ukugqitha ekujoliswe kuko kwe-ADA.

• Uphuculo olubalulekileyo kwi-glucose yokuzila ukutya kunye namanqanaba e-postprandial glucose yabonwa.

2. Ukunciphisa Ubunzima

I-Tirzepatide iveliswa rhoqoukuncipha kobunzima obunentsingiselo ngokwekliniki kunye nokuxhomekeka kwithamokubantu abanesifo seswekile nabangengabo abanesifo seswekile.

• Kwizigulane ze-T2DM: umyinge wokunciphisa ubunzima bomzimba ukusuka7-12 kg.

• Kubantu abatyebe kakhulu kwisifo seswekile (SURMOUNT-1 trial):

  • I-10 mg kunye ne-15 mg iidosi ezikhokelelaI-15-22% ithetha ukunciphisa umzimba, xa kuthelekiswa okanye ngaphaya kwemida yotyando lwe-bariatric.

• Uninzi lwabathathi-nxaxheba luphumelele ubuncinci5–10%ukunciphisa ubunzima.

3. Ukuphuculwa kweCardiometabolic

Unyango lwe-Tirzepatide luphucule iiparamitha zemetabolism ebanzi:

• Ukunciphisakwi-triglycerides, i-LDL-C, kunye ne-cholesterol epheleleyo.

• Ukonyukakwi-HDL-C.

• Kubalulekileukunciphisa uxinzelelo lwegazi lwe-systolic kunye ne-diastolic.

• Ukuphuculwa kokuqonda kwe-insulin kunye nokusebenza kwe-β-cell.

4. Ukhuseleko kunye nokunyamezeleka

Iprofayili yokhuseleko yayihambelana nolunye unyango olusekwe kwi-incretin:

• Uninzi lweziganeko ezibi ezixhaphakileyo: iimpawu zesisu ezisezantsi ukuya kwimodareyitha (isicaphucaphu, ukuhlanza, isifo sohudo).

• Izehlo ezisezantsi ze-hypoglycemia, ngakumbi xa isetyenziswa kunye ne-insulin okanye i-sulfonylureas.

• Akukho nkxalabo enkulu yokhuseleko ebonwe kwiziphumo ze-cardiovascular.

5. Iimbono zoomatshini

I-Tirzepatide iyodwaI-agonism ye-receptor ezimbiniyandisa zombini iindlela ze-GIP kunye ne-GLP-1:

• GIP ukusebenzaiphucula i-insulin exhomekeke kwi-glucose kwaye inokuphucula i-adipose tissue metabolism.

• GLP-1 isebenzeikhuthaza ukudakumba kokutya kwaye ilibazise ukukhupha isisu.

• Yaboisiphumo se-synergisticikhokelela ekuphuculeni ulawulo lwe-glucose kunye nokunciphisa ubunzima obuphuculweyo xa kuthelekiswa ne-agent yendlela enye.

Ukuqukumbela

I-Tirzepatide imele aimpumelelo kunyango lwe-metabolic, ukunikaukusebenza okungazange kubonwe ngaphambili kulawulo lwe-glycemic kunye nokunciphisa ubunzimakubantu abanesifo seswekile esi-2 kunye nokutyeba kakhulu.
Indlela yayo emibini ye-incretin ibonelela ngendlela edityanisiweyo yokulungisa oonobangela bokungasebenzi kakuhle kwe-metabolic-hyperglycemia, ukumelana ne-insulin, kunye nobunzima bomzimba obugqithisileyo.
Ngenxa yokusebenza kwayo ngamandla kunye neprofayili yokhuseleko olulawulekayo, i-tirzepatide inokuphinda ichaze i-paradigm yonyango yesifo seswekile kunye nolawulo lokutyeba kakhulu kwiminyaka elishumi ezayo.

Iimbekiselo

• UFrias JP et al.,New England Journal of Medicine, 2021.

• Jastreboff AM et al.,New England Journal of Medicine, 2022 (SURMOUNT-1).

• Ludvik B et al.,I-Lancet, 2021.

• U-Eli Lilly weDatha yoNyango, i-SURPASS izilingo 1-5.